Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Rituxan will be off patent in 2013 in Europe

Discussion in 'Rituximab: News and Research' started by fairlight, Jul 30, 2012.

  1. fairlight

    fairlight

    Messages:
    78
    Likes:
    3
  2. August59

    August59 Daughters High School Graduation

    Messages:
    1,617
    Likes:
    621
    Upstate SC, USA
    Rituximab is also in clinical trials for MS to, I think. Not sure what phase, but if they found enough uses for a generic rituximab it might make it profitable for someone to go after a generic version.
     
  3. shannah

    shannah Senior Member

    Messages:
    1,242
    Likes:
    1,185
  4. Sherlock

    Sherlock tart cherry etc. for joints, insomnia

    Messages:
    1,229
    Likes:
    674
    Czechosherlockia, USA
    Unfortunately, AFAIK no one is allowed still to make generic versions of biologic medications, even when off patent in the U.S. as per the FDA. The rationale is that they are too difficult to make properly.


    http://www.businessweek.com/stories...siness-news-stock-market-and-financial-advice

    more here: http://www.merckmanuals.com/home/drugs/trade-name_and_generic_drugs/generic_biologic_drugs.html

    But then, Europe and Mabthera might be different?
     

See more popular forum discussions.

Share This Page